Back to results
US 12,291,722 B2Granted
Methods for manufacturing adoptive cell therapies
Assignee2seventy bio, Inc.
InventorsRichard Morgan, Kevin Friedman, Dawn Maier
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for manufacturing adoptive cell therapies. In particular embodiments, the invention provides methods of harvesting populations of cells, isolating and activating PBMCs, expanding T cells, and administering the T cell therapeutic to a subject in need thereof.
Claims35
A method for manufacturing a human T cell therapeutic for a subject comprising:
- a) obtaining a population of human peripheral blood mononuclear cells (PBMCs) from the subject, wherein the PBMCs comprise CD4+ T cells, CD8+ T cells, and antigen presenting cells (APCs);
- b) culturing the population of PBMCs of step a) for about 20 hours to about 24 hours prior to transduction in a cell culture medium comprising i) one or more cytokines, ii) a soluble anti-CD3 antibody or CD3-binding fragment thereof, and iii) a soluble anti-CD28 antibody or a CD28-binding fragment thereof, thereby producing activated T cells;
- c) transducing the population of PBMCs of step b) comprising activated T cells with a lentiviral vector comprising a polynucleotide encoding an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR), thereby producing transduced T cells;
- and
- d) culturing the population of PBMCs of step c) in a cell growth medium to expand the number of the transduced T cells,
- thereby manufacturing the human T cell therapeutic for the subject.
3 more elements
A method for manufacturing a human T cell therapeutic comprising:
- a) providing a population of autologous human peripheral blood mononuclear cells (PBMCs) comprising CD4+ T cells, CD8+ T cells, and antigen presenting cells (APCs);
- b) culturing the population of PBMCs of step a) for about 20 hours to about 24 hours prior to transduction in a cell culture medium comprising i) one or more cytokines, ii) a soluble anti-CD3 antibody or CD3-binding fragment thereof, and iii) a soluble anti-CD28 antibody or a CD28-binding fragment thereof, thereby producing activated T cells;
- c) transducing the population of PBMCs of step b) comprising activated T cells with a lentiviral vector comprising a polynucleotide encoding an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR), thereby producing transduced T cells;
- and
- d) culturing the population of PBMCs of step c) in a cell growth medium to expand the number of the transduced T cells,
- thereby manufacturing the human T cell therapeutic.
3 more elements
Dependencies are inferred from the claim text.